|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
For that, mouse BM cells were transduced with lentiviral vectors coding for <i>VEGFA</i> or sphingosine kinase (<i>SPHK1)</i>, which catalyzes S1P production, and injected them intravenously 4 and 7 days after cardiac ischemia-reperfusion in mice.
|
30786776 |
2019 |
|
Myocardial Ischemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It is not clear whether treatment by vascular endothelial growth factor (VEGF) gene transfer can improve myocardial ischemia through a proangiogenesis mechanism and is effective against coronary artery disease (CAD).
|
30035366 |
2018 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that controlled homogeneous VEGF delivery by FACS-purified transduced ASC is a promising strategy to achieve safe and functional angiogenesis in myocardial ischaemia.
|
29478261 |
2018 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, our study provides proof of principle that nanoparticle-mediated delivery increases the angiogenic and therapeutic potency of VEGF for the treatment of ischemic heart disease.
|
29101176 |
2018 |
|
Myocardial Ischemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, VEGF rs699947 and rs2010963 polymorphisms may serve as genetic biomarkers of poor collateral circulation after myocardial ischemia.
|
30317903 |
2018 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study does not provide strong evidence for a positive effect of VEGF on IHD but does not rule out the possibility that some specific types of VEGF, for which genetic predictors have not yet been identified, might play a role.
|
28765276 |
2017 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings show that dysregulated angiogenic precursors link coronary anomalies to ischemic heart disease.Though coronary arteries are crucial for heart function, the mechanisms guiding their formation are largely unknown.Here, Wang et al. identify a unique, endocardially-derived angiogenic precursor cell population for coronary artery formation in mice and show that a DLL4/NOTCH1/VEGFA/VEGFR2 signaling axis is key for coronary artery development.
|
28924218 |
2017 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This in vitro study explored the effect of VEGF and serum deprivation on endothelial differentiation capacity of ASCs from healthy donors and IHD patients.
|
24047149 |
2013 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, VEGF microparticles and CoQ10 nanoparticles can be considered as promising strategies for managing MI.
|
23639291 |
2013 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thymosin beta-4 (TB4) and vascular endothelial growth factor (VEGF) are linked to adult epicardial progenitor cell mobilization and neovascularization and is cardioprotective after myocardial ischemia.
|
21332365 |
2011 |
|
Myocardial Ischemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analyses indicated that the strongest associations with IHD and MI were due to the combined effect of the VEGFA-2578 A allele and smoking (OR 3.52 and 7.11, respectively), independent of risk factors such as age, sex, diabetes, C-reactive protein, hypercholesterolemia, and hypertension.
|
21362767 |
2011 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hypoxia-inducible vascular endothelial growth factor gene therapy using the oxygen-dependent degradation domain in myocardial ischemia.
|
20607367 |
2010 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) is an important active protein for the induction of angiogenesis and improvement in cardiac function after myocardial ischemia; however, the lack of a delivery system targeted to the injured myocardium reduces the local therapeutic efficacy of VEGF and increases its possible adverse effects.
|
19307480 |
2009 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1.
|
18373738 |
2008 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor-A is widely used in clinical trials for the treatment of cardiac ischemia.
|
16990600 |
2007 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Cardioplegia prevents ischemia-induced transcriptional alterations of cytoprotective genes in rat hearts: a DNA microarray study.
|
16214533 |
2005 |
|
Myocardial Ischemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Cardioplegia prevents ischemia-induced transcriptional alterations of cytoprotective genes in rat hearts: a DNA microarray study.
|
16214533 |
2005 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review discusses proof of the concept pre-clinical studies and phase-I/II human trials using VEGF, and cellular angiogenesis at length in the light of the literature and analyzes the problems and considerations of these approaches as a treatment strategy in the clinical perspective for the treatment of ischemic heart disease.
|
14963670 |
2004 |
|
Myocardial Ischemia
|
0.400 |
Therapeutic
|
disease |
CTD_human |
PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease.
|
15347709 |
2004 |
|
Myocardial Ischemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because hypoxia-inducible factor (HIF)-1alpha is a transcriptional activator of vascular endothelial growth factor (VEGF) and is critical for initiating angiogenic responses to hypoxia, we investigated the expression of HIF-1alpha and VEGF in specimens of human heart tissue to elucidate the molecular responses to myocardial ischemia in diabetic patients during unstable angina.
|
15331549 |
2004 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mobilization of endothelial progenitor cells with cytokines potentiates VEGF-2 gene therapy for myocardial ischemia and enhances bone marrow cell incorporation into ischemic myocardium.
|
15337699 |
2004 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease.
|
15347709 |
2004 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs.
|
14503966 |
2003 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia.
|
14583313 |
2003 |
|
Myocardial Ischemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, with the localized induction of VEGF and the low cytotoxicity of WSLP, the pEpo-SV-VEGF/WSLP system may be helpful to eventually treat ischemic heart disease.
|
12907944 |
2003 |